The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) September 26, 2022
✳️ 10 tweet #NephJC catch-up ✳️
Did you ever think of using acetazolamide for acute congestive heart failure?
Read on to see whether we should or we should not! pic.twitter.com/e6XHi1JouG